A synthetic lethal screen identifies ATR-inhibition as a novel therapeutic approach for POLD1-deficient cancersSandra Hocke, Eike Gallmeier|Oncotarget|2016Cited by 41
Synthetic lethality between ATR and POLA1 reveals a potential new target for individualized cancer therapyHanna Schneider, Eike Gallmeier|Neoplasia|2024Cited by 5